A newly approved drug could help some rectal cancer patients avoid chemo, radiation and surgery.

GSK's Jemperli (dostarlimab-gxly) received FDA approval for advanced rectal cancer. The accelerated approval is based on AZUR-1 trial data showing 68% of patients achieved sustained clinical complete responses at 12 months. GSK reported no disease recurrences among responders after a median follow-up of over two years. The drug received Fast Track, Breakthrough Therapy, and Priority Review designations.

GSK received FDA accelerated approval for Jemperli to treat MSI-H/dMMR rectal cancer, supported by phase II data. This expands Jemperli's oncology indications, following prior approvals in gynecologic cancers, according to the company.

GSK (GSK) received FDA approval for its immunotherapy drug Jemperli, targeting a specific form of rectal cancer. The company offers a 3.58% dividend yield with a 39% payout ratio and a GF Score of 78/100. GSK's stock is trading at $49.59, 9.8% above its GF Value of $45.17. Institutional interest is mixed, with some gurus trimming positions while others add.

AnaptysBio (ANAB) announced FDA approval for GSK's Jemperli (dostarlimab) to treat locally advanced rectal cancer, based on AZUR-1 trial data. The drug showed significant clinical responses, potentially avoiding chemo, radiation, and surgery. GSK will present full data at ESMO Congress 2026. ANAB manages financial collaborations for Jemperli.

The FDA approved GSK's Jemperli for first-line treatment of MSI-High, dMMR rectal cancer. This expands the drug's approved uses, potentially increasing its market. GSK develops and markets Jemperli.

The FDA approved GSK's Jemperli for certain rectal cancers, offering a less invasive treatment option. The drug showed efficacy in clinical trials, with 75% of patients avoiding traditional treatments. GSK shares rose 0.32% to $49.67 on the news.